Skip to content

    Hepatitis Health Center

    Font Size
    A
    A
    A

    New Drug Cures Hard-to-Treat Hepatitis C

    3-Drug Treatment Coming Soon, Expert Says
    By
    WebMD Health News
    Reviewed by Laura J. Martin, MD

    April 7, 2010 -- Patients who fail current hepatitis C virus (HCV) treatments have few other options except trying the same drugs again, but an experimental antiviral drug is poised to change that.

    When the drug telaprevir was added to standard treatment with peginterferon alfa and ribavirin, which are also antivirals, about half of patients who had failed previous treatment with the two drugs cleared the virus.

    The patients showed no evidence of HCV infection six months after completing treatment, which is considered a cure.

    Telaprevir is one of two highly anticipated drugs in the class known as protease inhibitors being studied in patients with chronic hepatitis C infection, a condition that affects about 3 million Americans and is the leading cause of liver transplants in the U.S.

    Phase III trials are under way for telaprevir, manufactured by Vertex Pharmaceuticals, and boceprevir, manufactured by Schering-Plough.

    Saint Louis University HCV specialist Bruce Bacon, MD, says when the two drugs make it to the market, which may be as early as next year, they will change the face of hepatitis C treatment.

    Bacon did not participate in the new study, published in the April 8 issue of the New England Journal of Medicine.

    “Triple drug therapy is coming and it will mean cures for many more people,” he tells WebMD. “My patients are very excited about it.”

    Half of HCV Patients Cured

    About 40% of previously untreated HCV patients are cured with the current treatment regimen, which includes 48 weeks of peginterferon and ribavirin.

    A second round of treatment is often recommended for patients who fail to respond to initial treatment or who respond and then relapse. But this approach is not very effective.

    In their latest study, Duke University researcher John G. McHutchison, MD, and colleagues achieved higher cure rates in previously treated patients than has been reported before by adding telaprevir to the other two drugs.

    The study participants were randomly assigned to one of four treatment groups: 12 weeks of telaprevir and 24 weeks of interferon/ribavirin; 24 weeks of telaprevir and 48 weeks of interferon/ribavirin; 24 weeks of telaprevir and interferon without ribavirin; or 48 weeks of interferon/ribavirin without telaprevir.

    Today on WebMD

    Hepatitus C virus
    Types, symptoms and treatments.
    liver illustration
    Myths and facts about this essential organ.
     
    woman eating apple
    What you need to know.
    doctor and patient
    What causes it?
     
    Hepatitis C Treatment
    Article
    Syringes and graph illustration
    Tool
     
    liver illustration
    Quiz
    passport, pills and vaccine
    Slideshow
     
    Scientist looking in microscope
    Slideshow
    Fatty Liver Disease
    Article
     
    Digestive Diseases Liver Transplantation
    Article
    Picture Of The Liver
    Image Collection